/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic
/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.
Issuer: Immunic, Inc. / Key word(s): Personnel Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. 27.04.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. Strengthens Its Board of Directors with th.
Immunic Inc (IMUX) Appoints Richard Rudick to its Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.